Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBF Conditioning for Haplo-HSCT in Elderly High-Risk AML
NCT06869265Phase 2Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2025
- Primary completion
- Apr 2028
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of thiotepa, busulfan, fludarabine in acute myeloid leukemia (AML), sponsored by Peking University People's Hospital. Started May 2025; status: recruiting.
02
Drugs
thiotepabusulfanfludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06869265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06869265.